We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+22.24%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$4.28M
AUM Growth
-$18.6M
Cap. Flow
-$19.2M
Cap. Flow %
-449.06%
Top 10 Hldgs %
99.37%
Holding
14
New
2
Increased
2
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$233K
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$56.5K
3
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$29.4K
4
IKT icon
Inhibikase Therapeutics
IKT
+$19.2K

Top Sells

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$18.7M
2
ELVN icon
Enliven Therapeutics
ELVN
+$268K
3
BCAX
Bicara Therapeutics
BCAX
+$173K
4
DFTX
Definium Therapeutics
DFTX
+$140K
5
GLD icon
SPDR Gold Trust
GLD
+$123K

Sector Composition

Rank Sector Weight
1 Healthcare 27.17%
2 Financials 8.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLD icon
1
SPDR Gold Trust
GLD
$130B
$2.76M 64.5%
6,964
-322
-4% -$123K
BRK.B icon
2
Berkshire Hathaway Class B
BRK.B
$1.06T
$357K 8.34%
710
+59
+9% +$29.4K
SYRE icon
3
Spyre Therapeutics
SYRE
$8.7B
$292K 6.83%
+8,919
New +$233K
DFTX
4
Definium Therapeutics
DFTX
$5.88B
$210K 4.91%
15,688
-11,323
-42% -$140K
KYTX icon
5
Kyverna Therapeutics
KYTX
$453M
$176K 4.12%
18,773
-4,208
-18% -$31.2K
CMPX icon
6
Compass Therapeutics
CMPX
$369M
$158K 3.7%
29,495
-24,008
-45% -$111K
LXEO icon
7
Lexeo Therapeutics
LXEO
$368M
$138K 3.24%
13,943
-3,389
-20% -$30.9K
XFOR icon
8
X4 Pharmaceuticals
XFOR
$360M
$62.2K 1.45%
+15,557
New +$56.5K
IKT icon
9
Inhibikase Therapeutics
IKT
$331M
$58.3K 1.36%
28,453
+12,060
+74% +$19.2K
SABS icon
10
SAB Biotherapeutics
SABS
$271M
$39.4K 0.92%
10,527
-408
-4% -$1.34K
CNTX icon
11
Context Therapeutics
CNTX
$55.1M
$27.1K 0.63%
18,403
– –
ELVN icon
12
Enliven Therapeutics
ELVN
$3.8B
– –
-13,097
Closed -$268K
RZLT icon
13
Rezolute
RZLT
$444M
– –
-1,986,818
Closed -$18.7M
BCAX
14
Bicara Therapeutics
BCAX
$1.82B
– –
-10,941
Closed -$173K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q4 2025 Portfolio in Review

As of Q4 2025, Caxton Corporation held 14 positions worth $4.28M, down 81% from $22.9M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Caxton Corporation withdrew a net $19.2M in Q4 2025, closing 3 positions and reducing 6 holdings. Its most notable exit was Rezolute, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 87% a quarter earlier, followed by Financials.

Against the trend, Caxton Corporation opened a new position in Spyre Therapeutics worth $292K.

  • Caxton Corporation's largest Q4 2025 buy was Spyre Therapeutics: 8,919 shares worth $292K.
  • Caxton Corporation added most to Berkshire Hathaway Class B in Q4 2025, an estimated $29.4K increase.
  • Caxton Corporation's biggest Q4 2025 reduction was Definium Therapeutics, cutting an estimated $140K.
  • Caxton Corporation fully exited Rezolute in Q4 2025, selling an estimated $18.7M.
  • Caxton Corporation's ten largest holdings make up 99% of its $4.28M portfolio in Q4 2025.
  • Caxton Corporation opened 2 new positions and closed 3 in Q4 2025.
  • Caxton Corporation's portfolio value fell 81% quarter-over-quarter to $4.28M.

Based on Caxton Corporation's 13F filing for Q4 2025, filed 13 Feb 2026.